Where things stand

YouGov's (LSE:YOU) latest filing, on Friday 13 November 2026, reported that it had bought 100,220 of its own shares between 9 and 13 November under the buyback launched in October, and intends to cancel them. That is routine. Two larger decisions are now pending at the market clinical-trial group: the outcome of a strategic review of its Shopper division, launched in March, and the handover to a new chief executive, Wayne Levings, who was due to join as chief executive-elect in November and to take over no later than February 2027.

Why Shopper matters

Shopper, which YouGov (LSE:YOU) added through an acquisition, is the group's largest division by revenue. In the year to 31 July 2026 its Revenue rose 1% on a reported basis to £129.5m but fell 1% on an underlying basis, and the company cited increased competitive activity. Adjusted operating profit dropped to £18.2m from £27.2m, cutting its Margin to 14% from 21%, which the company attributed to a targeted Investment programme to expand panels and strengthen the client offer.

That investment explains most of the group's profit decline. Group revenue increased 2% to £396.6m while adjusted operating profit fell 11% to £54.3m. The company (LSE:YOU) said its margin would have stayed at 16% excluding the Shopper spending. By contrast, Data Products lifted adjusted operating profit to £28.9m at a 34% margin, and Clinical-trial earned £18.6m at 10%.

Regional figures show its weight. The company said mainland Europe revenue fell 1% on an underlying basis because of the division, while the Americas grew 6% and UK 1%. Tax payments rose to £13.9m from £6.1m, which the company explained by the settlement of prior-year tax in Shopper. Amortisation fell by £4.8m because order Backlog Assets from the Shopper Acquisition had been fully amortised by the 2025 financial year.

What the board has said

The chair, Ian Griffiths, said the strategic rationale for the acquisition remained unchanged, that the review was continuing and that an update would follow in due course. Management said Shopper investment would run at broadly the same level in the 2027 financial year, with benefits expected during that year. No options, adviser or timetable for the review have been disclosed, and the company has not said whether a sale is being considered.

Leadership and board turnover

The review overlaps with extensive change at the top. Stephan Shakespeare, the co-founder who returned as chief executive in February 2025, will move to a non-executive role and chair a new Innovation Committee after the handover. The chief financial officer left in February and James Davies serves on an interim basis, off the board. A long-serving non-executive is not standing for re-election at the AGM, and the board expects to appoint two non-executives during the year.

Factors to watch

The statutory accounts show why the review matters. Separately reported items reached £33.1m, including £17.5m of non-cash impairments, among them £9.5m against Goodwill that the company linked partly to its DACH Business and to a higher discount rate in that region. A decision on Shopper could trigger further accounting charges or restructuring costs, and a sale would change group scale and Earnings mix. Year-end net Debt was £142.1m, with Leverage of 1.7 times. A new chief executive will also want a say on the outcome, which could affect timing.

Guidance and next steps

The company guided to adjusted operating profit of £58m to £61m for the year to July 2027, growth of 7% to 12%, and said 49% of expected revenue was already contracted. Its Annual Report and notice of AGM were posted on 4 November. The interim results for the half to 31 January 2027 are the next scheduled financial update, and any Shopper conclusion would be announced separately.